Value of different Baveno Ⅶ-based criteria in screening for high-risk esophageal and gastric varices in advanced chronic liver disease

Chunmei GUO; Hong LIU; Yadan WANG; Mingming MENG; Canghai WANG; Hui SU; Jing WU

doi:10.3969/j.issn.1001-5256.2023.04.012

Volume 39 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(4): 818-825

PDF( 2878 KB)

Value of different Baveno Ⅶ-based criteria in screening for high-risk esophageal and gastric varices in advanced chronic liver disease

DOI: 10.3969/j.issn.1001-5256.2023.04.012

1.
Department of Gastroenterology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
2.
Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China

Research funding:

National Natural Science Foundation of China Youth Fund (81900505);

The Science and Technology Development Project of China State Railway Group (J2021Z609)

More Information

Corresponding author: WU Jing, wujing36youyi@ccmu.edu.cn (ORCID: 0000-0002-8255-1953)
Received Date: 2022-09-13
Accepted Date: 2022-11-09
Published Date: 2023-04-20

Abstract

Abstract

Objective To investigate the value of Baveno Ⅶ criteria versus Expanded Baveno Ⅶ criteria in screening for high-risk varices (HRV) in patients with compensated advanced chronic liver disease (cACLD). Methods A total of 146 patients with cACLD who were admitted to Beijing Shijitan Hospital, Capital Medical University, from January 2016 to December 2018 were enrolled, and according to the absence or presence of HRV based on gastroscopy, they were divided into HRV group with 68 patients and control group with 78 patients. Clinical data, liver stiffness measurement (LSM), and gastroscopy findings were analyzed, and different Baveno Ⅶ criteria were analyzed in terms of their sensitivity and specificity in the diagnosis of HRV. The Mann-Whitney U test and the McNemar test were used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. A univariate logistic regression analysis was performed for the variables used to predict HRV, and a multivariate analysis was performed for the variables with P < 0.1. The two sets of Baveno Ⅶ criteria were compared in terms of their sensitivity and specificity in the diagnosis of HRV. Results A total of 146 patients were enrolled in the study, among whom 68 (46.6%) were found to have HRV. The median age was 54 years (range 29-84 years), male patients accounted for 65.8%, and hepatitis B virus was the main etiology observed in 115 patients (78.8%). The univariate logistic regression analysis showed that LSM and platelet count (PLT) were associated with HRV (both P < 0.05). The multivariate analysis showed that based on Baveno Ⅶ criteria, LSM > 20 kPa or PLT < 150×10⁹/L was associated with HRV (both P < 0.05), and based on Expanded Baveno Ⅶ criteria, LSM > 25 kPa or PLT < 110×10⁹/L was associated with HRV (both P < 0.05). LSM and PLT had an area under the ROC curve of 0.797 (95% confidence interval [CI]: 0.723-0.859) and 0.789 (95% CI: 0.714-0.852), respectively, in the diagnosis of HRV. There were significant differences in the prevalence rates of esophageal and gastric varices and HRV between the patients who met Baveno Ⅶ criteria and those who did not meet such criteria (χ²=23.14 and 23.14, both P < 0.001), as well as between the patients who met Expanded Baveno Ⅶ criteria and those who did not meet such criteria (χ²=43.51 and 25.71, both P < 0.001). Although a higher proportion of patients were exempted from gastroscopy based on Expanded Baveno Ⅶ criteria (32.9% vs 13.7%), Baveno Ⅶ criteria had higher sensitivity (0.98 vs 0.88) and negative predictive value (0.95 vs 0.83) and could better avoid the missed diagnosis of HRV (1.0% vs 9.3%). Conclusion Baveno Ⅶ criteria are more suitable for the screening for HRV in cACLD patients in China.
- BavenoⅦ Criteria,
- Esophageal and Gastric Varices,
- Liver Cirrhosis

FullText(HTML)

非酒精性脂肪性肝病(NAFLD)是指除外酒精和其他明确的损肝因素所致肝脏细胞内脂肪过度沉积(＞5%)为主要特征的一种临床病理综合征^[1]。NAFLD是与胰岛素抵抗和遗传易感性密切相关的一种获得性代谢应激性肝损伤^[2]，随着肥胖及其相关代谢综合征全球化的流行趋势，NAFLD现已成为欧美等发达国家和我国相对富裕地区慢性肝病的重要病因。NAFLD疾病谱包括非酒精性肝脂肪变、非酒精性脂肪性肝炎(NASH)、肝硬化和肝细胞癌(HCC)^[3]。

尿酸是内源性和外源性嘌呤核苷酸代谢的终产物，血清尿酸(serum uric acid，sUA)产生过多或排泄减少可导致sUA升高，即为高尿酸血症(hyperuricemia，HUA)。HUA可引起全身系统的损害，并与代谢综合征密切相关。研究^[4]显示，sUA/肌酐(serum creatinine，Cr)比值与代谢综合征显著相关。本研究着眼于sUA/Cr与NAFLD发生的相关性，以期对NAFLD的诊疗提供进一步的依据。

1. 资料与方法

1.1 研究对象

回顾性选取2020年1月—2020年12月就诊于本院的97例NAFLD患者(NAFLD组)。另选取同期于本院体检的36例健康成人作为对照组。NAFLD诊断标准：根据《非酒精性脂肪性肝病防治指南(2018年更新版)》^[2]中相关诊断标准，年龄≥18岁。排除标准：(1)已确诊的糖尿病、高血压患者，慢性肾功能衰竭(肾小球滤过率＜30 mL/min)、肿瘤等严重的急慢性病患者；(2)酒精性、病毒性、药物性、自身免疫性、全胃肠外营养等明确病因所致肝脏疾病患者。

1.2 NAFLD超声分级标准

(1) 肝肾对比或肝肾回声差异，肝实质回声明显大于肾实质回声；(2)肝脏近场和远场回声差异，近场回声增强，远场则衰减；(3)肝内管道结构特别是静脉内径变细，显示不清；(4)肝脏各径线测值存在不同程度增大；(5)彩色血流显示肝脏中血流信号不同程度存在减少；(6)肝右叶包膜及横膈回声显示不清晰。轻度脂肪肝：满足(1)与其余任何一项的情况。中度脂肪肝：满足(1)以及其余任何2项的情况。重度脂肪肝：满足(1)及其余任何3项的情况^[5]。

1.3 资料收集

收集所有研究对象的性别、年龄、空腹血糖(fasting blood sugar，FBS)、ALT、AST、TC、TG、高密度脂蛋白胆固醇(HDL)、低密度脂蛋白胆固醇(LDL)、GGT、sUA、sCr、sUA/Cr，以及腹部超声结果。

1.4 伦理学审查

本研究方案经由首都医科大学附属北京天坛医院伦理委员会审批，批号：KY2016-042-01。

1.5 统计学方法

采用SPSS 18.0软件对所有数据进行统计学分析。正态分布的计量资料以x ±s表示，2组间比较采用独立样本t检验，3组间比较采用方差分析；非正态分布数据以M(P₂₅~P₇₅)表示，组间比较采用Mann-Whitney U检验；计数资料组间比较采用χ²检验；相关性分析采用Spearman检验。采用logistic回归分析NAFLD相关的危险因素。P＜0.05为差异有统计学意义。

2. 结果

2.1 一般资料

NAFLD组ALT、AST、TG、GGT、sUA、sUA/Cr水平均显著高于健康对照组，而HDL水平则显著低于健康对照组(P值均＜0.05)(表 1)。

表 1 NAFLD组与健康对照组临床资料比较

项目	NAFLD组(n=97)	健康对照组(n=36)	统计值	P值
男性[例(%)]	62(63.9)	25(69.4)	χ²=0.354	0.682
年龄(岁)	44(34~55)	39(34~52)	Z=-1.353	0.176
FBS(mmol/L)	5.15(4.69~6.28)	5.05(4.78~5.39)	Z=-1.473	0.141
ALT(U/L)	36.7(21.5~58.6)	14.6(11.6~20.0)	Z=-4.881	＜0.001
AST(U/L)	23.6(18.4~35.7)	15.6(13.5~17.8)	Z=-4.616	＜0.001
TC(mmol/L)	4.53(3.66~5.37)	4.67(3.88~5.23)	Z=-0.765	0.444
TG(mmol/L)	1.71(1.03~2.72)	0.95(0.62~1.32)	Z=-4.221	＜0.001
HDL(mmol/L)	1.14(1.00~1.38)	1.58(1.43~1.88)	Z=-5.682	＜0.001
LDL(mmol/L)	2.70±0.97	2.69±0.93	t=0.003	0.958
GGT(U/L)	39.46(20.31~55.72)	19.21(11.95~31.05)	Z=-3.563	＜0.001
sUA(μmmol/L)	363.46±95.75	294.27±92.36	t=12.974	＜0.001
sCr(μmmol/L)	63.20±19.19	58.37±14.93	t=1.723	0.192
sUA/Cr	6.04±1.60	5.05±1.11	t=10.710	0.001

下载: 导出CSV

| 显示表格

2.2 NAFLD脂肪肝严重程度与各指标相关性分析

随着脂肪肝严重程度的加重，NAFLD患者ALT、AST、TC、TG、LDL、GGT水平均显著升高(P值均＜0.05)(表 2)。相关性分析显示，NAFLD的脂肪肝严重程度(轻中重)与ALT(r=0.291，P=0.004)、TC(r=0.272，P=0.010)、LDL(r=0.253，P=0.017)水平呈正相关。

表 2 轻中重度NAFLD患者临床资料比较

项目	轻度NAFLD组(n=33)	中度NAFLD组(n=31)	重度NAFLD组(n=33)	统计值	P值
男性[例(%)]	23(69.7)	21(67.7)	18(54.5)	χ²=1.931	0.381
年龄(岁)	54(44~60)	42(34~61)	38(32~52)	Z=7.574	0.023
FBS(mmol/L)	5.11(4.39~6.12)	5.34(4.79~7.28)	5.29(4.76~6.12)	Z=2.937	0.230
ALT(U/L)	20.23(14.05~32.45)	45.30(24.20~76.51)	46.55(33.65~77.88)	Z=19.181	＜0.001
AST(U/L)	19.20(15.25~25.65)	26.40(20.00~41.30)	29.55(21.58~46.83)	Z=11.969	0.003
TC(mmol/L)	4.07(3.44~4.73)	4.62(3.57~4.97)	5.03(4.27~5.64)	Z=9.097	0.011
TG(mmol/L)	1.32(0.85~2.39)	1.41(1.05~2.12)	2.16(1.25~2.89)	Z=6.333	0.042
HDL(mmol/L)	1.13(0.98~1.35)	1.14(1.00~1.38)	1.23(1.02~1.45)	Z=1.100	0.577
LDL(mmol/L)	2.51±1.00	2.48±0.85	3.10±0.93	F=4.175	0.019
GGT(U/L)	24.30(16.05~47.80)	40.6(30.00~65.70)	42.15(30.05~57.45)	Z=7.667	0.022
sUA(μmmol/L)	349.55±109.80	368.60±100.52	372.28±76.64	F=0.466	0.629
sCr(μmmol/L)	62.44±16.03	68.21±24.99	59.08±14.32	F=1.855	0.162
sUA/Cr	5.72±1.48	5.95±1.86	6.45±1.42	F=1.648	0.199

下载: 导出CSV

| 显示表格

2.3 NAFLD发生的危险因素logistic回归分析

多因素logistic回归分析结果显示，年龄、HDL水平、sUA/Cr是发生NAFLD的独立影响因素(P值均＜0.05)(表 3)。

表 3 NAFLD发生的影响因素logistic回归分析

因素	OR	95%CI	B值	Wald值	P值
年龄(岁)	1.056	1.005~1.109	0.055	4.735	0.030
HDL(mmol/L)	0.023	0.003~0.186	-3.788	12.423	＜0.001
sUA/Cr	1.885	1.162~3.060	0.634	6.584	0.010

下载: 导出CSV

| 显示表格

3. 讨论

NAFLD是全球最常见的慢性肝病之一，世界范围内约有25%的人罹患NAFLD^[6]。近几十年来，随着人们生活方式、饮食结构的改变，NAFLD发病率不断上升，已成为我国第一大慢性肝病以及健康体检肝生物化学指标异常的最常见原因。目前认为，NAFLD与代谢综合征、胰岛素抵抗、糖尿病以及心血管疾病的风险增加有关^[7]。近10年间，NASH所致的肝移植率已从1.2%增加至9.7%^[8]。因此，寻找高效的NAFLD发生风险预测工具成为目前研究的热点。

尿酸主要由腺苷酸和鸟嘌呤分解后形成。研究^[9]显示，高尿酸血症是高血压病、脑卒中、动脉粥样硬化的独立危险因素。高尿酸血症也是代谢综合征的重要组分之一。尿酸在脂肪代谢中具有重要作用。即使是正常范围内sUA的水平升高，也与高脂血症、动脉硬化等具有显著相关性^[10]。Ali等^[11]研究指出，高尿酸血症是脂肪组织中促炎性细胞分泌失衡的重要介质，sUA与TG、TC和LDL水平呈显著正相关，与HDL呈负相关。诸多研究提示血尿酸水平与NAFLD具有显著的相关性。Afzali等^[12]研究指出，sUA与肝硬化的发展及肝酶升高具有显著相关性。尿酸的代谢与肾脏功能密切相关，尿酸经肾脏排出减少即会引起高尿酸血症。Kawamoto等^[13]指出，sUA/Cr水平是代谢综合征的独立预测因子。目前，国内尚未有sUA/Cr与NAFLD相关性的研究。

本研究NAFLD组ALT、AST、TG、GGT、sUA水平均显著高于健康对照组，HDL水平显著低于健康对照组，FBS、TC、LDL、GGT及sCr水平无明显差异。既往有Hwang等^[14]以及Moon等^[15]的研究已经指出sUA与NAFLD的相关性，本研究结果同样证实了这一结论。氧化应激是NAFLD发生的关键因子^[16]，sUA可能通过起到促氧化剂的作用，并与氧化剂发生反应，诱导产生自由基和氧化应激，从而影响NAFLD的发生。Xu等^[17]研究显示，NAFLD显著增加了高尿酸血症的发病风险，并指出黄嘌呤氧化酶可能是介导NAFLD患者发生高尿酸血症的重要因子。sUA通肾脏排泄，sUA的清除通常受肾功能的影响，而既往研究大都没有考虑到肾脏的影响。sUA/Cr较sUA更能准确地反映内源性UA水平。本研究结果显示，NAFLD组sUA/Cr水平均显著高于健康对照组。而多因素logistic回归分析结果显示，sUA/Cr是NAFLD的独立危险因素。Seo等^[18]研究显示，健康成人sUA/Cr升高与NAFLD具有显著相关性，故指出sUA/Cr可作为预测NAFLD的可靠指标。这与本研究结果一致。根据腹部超声检测结果，根据脂肪肝严重程度分为轻、中、重度3组，结果显示，随着NAFLD患者脂肪肝严重程度的加重，其ALT、AST、TC、TG、LDL、GGT水平显著升高。相关性分析结果显示，ALT、TC、LDL与NAFLD的严重程度呈正相关。因此，虽然sUA/Cr是NAFLD的独立危险因素，尚无法通过检测sUA/Cr水平来预测NAFLD的严重程度。

综上所述，鉴于NAFLD在世界范围内的高发病率，亟需一种非侵入性、成本效益高的筛查工具来预测存在潜在NAFLD风险的患者。本研究结果显示，sUA/Cr水平升高与成人罹患NAFLD有很强的相关性。NAFLD受试者的sUA水平和sUA/Cr均显著升高，即使校正了混杂因素，NAFLD的患病风险也与sUA/Cr升高有关。因此，可以通过监测sUA/Cr水平判断NAFLD的风险，以早期采取改善生活方式乃至药物等有效的干预措施预防NAFLD的发生，延缓NAFLD进展并改善患者预后。

References(29)

References

[1]	D'AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231. DOI: 10.1016/j.jhep.2005.10.013.
[2]	FORTUNE BE, GARCIA-TSAO G, CIARLEGLIO M, et al. Child-turcotte-pugh class is best at stratifying risk in variceal hemorrhage: analysis of a us multicenter prospective study[J]. J Clin Gastroenterol, 2017, 51(5): 446-453. DOI: 10.1097/MCG.0000000000000733.
[3]	SUN X, ZHANG A, ZHOU T, et al. Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial[J]. Hepatol Int, 2021, 15(3): 741-752. DOI: 10.1007/s12072-021-10155-0.
[4]	KIM DJ, CHOI MS. Life-sustaining treatment and palliative care in patients with liver cirrhosis-legal, ethical, and practical issues[J]. Clin Mol Hepatol, 2017, 23(2): 115-122. DOI: 10.3350/cmh.2017.0018.
[5]	LAU J, YU Y, TANG R, et al. Timing of endoscopy for acute upper gastrointestinal bleeding[J]. N Engl J Med, 2020, 382(14): 1299-1308. DOI: 10.1056/NEJMoa1912484.
[6]	GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
[7]	SUK KT. Hepatic venous pressure gradient: clinical use in chronic liver disease[J]. Clin Mol Hepatol, 2014, 20(1): 6-14. DOI: 10.3350/cmh.2014.20.1.6.
[8]	STAFYLIDOU M, PASCHOS P, KATSOULA A, et al. Performance of Baveno Ⅵ and Expanded Baveno Ⅵ criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2019, 17(9): 1744-1755. e11. DOI: 10.1016/j.cgh.2019.04.062.
[9]	AUGUSTIN S, PONS M, MAURICE JB, et al. Expanding the Baveno Ⅵ criteria for the screening of varices in patients with compensated advanced chronic liver disease[J]. Hepatology, 2017, 66(6): 1980-1988. DOI: 10.1002/hep.29363.
[10]	IRANMANESH P, VAZQUEZ O, TERRAZ S, et al. Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma[J]. J Hepatol, 2014, 60(5): 969-974. DOI: 10.1016/j.jhep.2013.12.015.
[11]	PONS M, AUGUSTIN S, SCHEINER B, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease[J]. Am J Gastroenterol, 2021, 116(4): 723-732. DOI: 10.14309/ajg.0000000000000994.
[12]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy, Chinese Medical Association. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
[13]	ABRALDES JG, BUREAU C, STEFANESCU H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The"Anticipate"study[J]. Hepatology, 2016, 64(6): 2173-2184. DOI: 10.1002/hep.28824.
[14]	QI XL. New techniques for diagnosis and monitoring of portal hypertension in liver cancer (Part)[J/CD]. Chin J Exp Clin Infect Dis (Electronic Edition), 2021, 15(1): 72. DOI: 10.3877/cma.j.issn.1674-1358.2021.01.101. 祁小龙. 肝癌门静脉高压症诊断与监测新技术(上)[J/CD]. 中华实验和临床感染病杂志(电子版), 2021, 15(1): 72. DOI: 10.3877/cma.j.issn.1674-1358.2021.01.101.
[15]	QI XL. New techniques for diagnosis and monitoring of portal hypertension in liver cancer (Part Ⅱ)[J/CD]. Chin J Exp Clin Infect Dis (Electronic Edition), 2021, 15(2): 144. DOI: 10.3877/cma.j.issn.1674-1358.2021.02.101 祁小龙. 肝癌门静脉高压症诊断与监测的新技术(下)[J/CD]. 中华实验和临床感染病杂志(电子版), 2021, 15(2): 144. DOI: 10.3877/cma.j.issn.1674-1358.2021.02.101
[16]	REVERTER E, TANDON P, AUGUSTIN S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding[J]. Gastroenterology, 2014, 146(2): 412-419. e3. DOI: 10.1053/j.gastro.2013.10.018.
[17]	European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1): 237-264. DOI: 10.1016/j.jhep.2015.04.006.
[18]	PALANIYAPPAN N, COX E, BRADLEY C, et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol, 2016, 65(6): 1131-1139. DOI: 10.1016/j.jhep.2016.07.021.
[19]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[20]	BUCK M, GARCIA-TSAO G, GROSZMANN RJ, et al. Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients[J]. Hepatology, 2014, 59(3): 1052-1059. DOI: 10.1002/hep.26755.
[21]	WANG S, HUANG Y, HU W, et al. Detachable string magnetically controlled capsule endoscopy for detecting high-risk varices in compensated advanced chronic liver disease (CHESS1801): A prospective multicenter study[J]. Lancet Reg Health West Pac, 2021, 6: 100072. DOI: 10.1016/j.lanwpc.2020.100072.
[22]	CHANG PE, TAN CK, CHEAH CC, et al. Validation of the Expanded Baveno-Ⅵ criteria for screening gastroscopy in asian patients with compensated advanced chronic liver disease[J]. Dig Dis Sci, 2021, 66(4): 1343-1348. DOI: 10.1007/s10620-020-06334-y.
[23]	HU Y, WEN Z. Validation and comparison of non-invasive prediction models based on liver stiffness measurement to identify patients who could avoid gastroscopy[J]. Sci Rep, 2021, 11(1): 150. DOI: 10.1038/s41598-020-80136-0.
[24]	DAJTI E, RAVAIOLI F, COLECCHIA A, et al. Are the Expanded Baveno Ⅵ Criteria really safe to screen compensated cirrhotic patients for high-risk varices?[J]. Dig Liver Dis, 2019, 51(3): 456-457. DOI: 10.1016/j.dld.2018.12.013.
[25]	KANG Y, PARK S, KIM S, et al. Validating the BAVENO Ⅵ criteria to identify low risk biliary atresia patients without endoscopy for esophageal varix[J]. Clin Res Hepatol Gastroenterol, 2021, 45(1): 101437. DOI: 10.1016/j.clinre.2020.04.007.
[26]	ZHENG KI, LIU C, LI J, et al. Validation of Baveno Ⅵ and expanded Baveno Ⅵ criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis[J]. J Hepatol, 2020, 73(6): 1571-1573. DOI: 10.1016/j.jhep.2020.06.042.
[27]	THABUT D, BUREAU C, LAYESE R, et al. Validation of Baveno Ⅵ criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy[J]. Gastroenterology, 2019, 156(4): 997-1009. e5. DOI: 10.1053/j.gastro.2018.11.053.
[28]	GIANNINI EG, de MARIA C, CRESPI M, et al. Course of oesophageal varices and performance of noninvasive predictors following hepatitis C virus clearance in compensated advanced chronic liver disease[J]. Eur J Clin Invest, 2020, 50(5): e13231. DOI: 10.1111/eci.13231.
[29]	LEE HA, KIM SU, SEO YS, et al. Prediction of the varices needing treatment with non-invasive tests in patients with compensated advanced chronic liver disease[J]. Liver Int, 2019, 39(6): 1071-1079. DOI: 10.1111/liv.14036.

Relative Articles

[1]	Peipei GUO, Yang XU, Jiaqi SHI, Yang WU, Lixia LU, Bin LI, Xiaohui YU. Role of amino acid metabolism in autoimmune hepatitis and related therapeutic targets[J]. Journal of Clinical Hepatology, 2025, 41(3): 547-551. doi: 10.12449/JCH250323
[2]	Yongping LIU, Yaojie SHEN. Clinical diagnosis of drug-induced autoimmune-like hepatitis[J]. Journal of Clinical Hepatology, 2025, 41(3): 542-546. doi: 10.12449/JCH250322
[3]	Mingming ZHANG, Huan LIU, Dongmei ZHANG, Dongbo WU, Hong TANG. Primary biliary cholangitis-autoimmune hepatitis overlap syndrome comorbid with pulmonary cryptococcosis： A case report[J]. Journal of Clinical Hepatology, 2024, 40(8): 1666-1669. doi: 10.12449/JCH240825
[4]	Wenjun YANG. Pathological diagnosis of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1082-1087. doi: 10.12449/JCH240603
[5]	Zhurong LI, Chen CHEN, Di GUO, Sixue LYU, Jiawen WU, Na YANG, Yang LIU. Role and mechanism of action of Yinchenhao Decoction in inhibiting ferroptosis of hepatocytes in mice with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(3): 502-508. doi: 10.12449/JCH240311
[6]	Xiaodong TENG. Value of biopsy in evaluating the pathological progression of autoimmune hepatitis/pancreatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1073-1075. doi: 10.12449/JCH240601
[7]	Qinrong LI, Ying YAO, Zhiyuan XU. Research advances in drug-induced autoimmune-like hepatitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1255-1258. doi: 10.12449/JCH240628
[8]	Xia SHENG, Qingming JI, Xinyu LI, Lihong WANG, Junqi NIU. Advances in drug therapy for primary sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(5): 1032-1038. doi: 10.12449/JCH240526
[9]	Xuexin WANG, Yingxia LI, Libin JIANG, Mingxia ZHOU, Dapeng WEI, Xiaopeng ZHANG, Hongtao WEN. Diagnostic value of real-time shear wave elastography for liver fibrosis in patients with autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2023, 39(1): 97-103. doi: 10.3969/j.issn.1001-5256.2023.01.015
[10]	Shixiu PENG, Chunyan LI, Aiping HUANG, Songtao ZHU, Jing MAI, Liping WU. Human immunodeficiency virus infection comorbid with autoimmune hepatitis－primary biliary cholangitis overlap syndrome： A case report[J]. Journal of Clinical Hepatology, 2023, 39(9): 2175-2178. doi: 10.3969/j.issn.1001-5256.2023.09.021
[11]	Longlong LUO, Lifei WANG, Ying ZHENG, Bin LI, Lixia LU, Chuyi LI, Xiaohui YU, Jiucong ZHANG. Research advances in mesenchymal stem cells and their exosomes in treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2023, 39(12): 2920-2925. doi: 10.3969/j.issn.1001-5256.2023.12.025
[12]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary sclerosing cholangitis (2021)[J]. Journal of Clinical Hepatology, 2022, 38(1): 50-61. doi: 10.3760/cma.j.cn112138-20211109-00786
[13]	Yu WANG, Min WANG, Guanhua ZHANG, Fuliang HE, Xiaojuan OU, Jidong JIA. Clinical diagnosis, staging, and therapeutic principles of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 17-21. doi: 10.3969/j.issn.1001-5256.2021.01.004
[14]	Hang DING, Linlin ZHENG, Yuan LIU, Lianfeng ZHANG, Lin ZHOU. Clinical features and prognosis of autoimmune pancreatitis alone or with IgG4-related sclerosing cholangitis[J]. Journal of Clinical Hepatology, 2021, 37(4): 888-892. doi: 10.3969/j.issn.1001-5256.2021.04.032
[15]	Chen Wei, Hong RuTao, Liu XiaoChang, Hu HuaQing. Value of fibrosis-4,aspartate aminotransferase-to-platelet ratio index,and globulin-platelet index in the diagnosis of significant liver fibrosis in autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1955-1959. doi: 10.3969/j.issn.1001-5256.2020.09.009
[16]	Wang Lu, Han Ying. An excerpt of British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis (2019)[J]. Journal of Clinical Hepatology, 2019, 35(9): 1937-1941. doi: 10.3969/j.issn.1001-5256.2019.09.010
[17]	Zhou GuiQin, Zhong QiHua, Wang RongBing, Dong XiaoDong, Li Bin, Yang Li, Wang XianBo. Value of fibrosis-4 index in diagnosis of liver fibrosis in autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2017, 33(8): 1487-1491. doi: 10.3969/j.issn.1001-5256.2017.08.015
[18]	Han Ying, Zhu JiangYi. An interpretation of recommendations for expert consensus on the diagnosis and treatment of primary sclerosing cholangitis(2015)[J]. Journal of Clinical Hepatology, 2016, 32(3): 420-422. doi: 10.3969/j.issn.1001-5256.2016.03.003
[19]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and management of primary sclerosing cholangitis(2015)[J]. Journal of Clinical Hepatology, 2016, 32(1): 23-31. doi: 10.3969/j.issn.1001-5256.2016.01.003
[20]	Wang QianYi, Jia JiDong. Advances in diagnosis and treatment of autoimmune hepatitis[J]. Journal of Clinical Hepatology, 2015, 31(2): 160-162. doi: 10.3969/j.issn.1001-5256.2015.02.003

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	吴卓青，郭崇慧，陈静锋，郑云超，丁素英. 非酒精性脂肪肝风险人群分层健康管理框架及多维代谢指标数据挖掘方法. 系统管理学报. 2024(04): 959-972 .
2.	葛宇，王超群，陈怡，沈若宇，董旭. 血清尿酸肌酐比值与非肥胖型代谢相关脂肪性肝病的相关性分析. 肝脏. 2024(08): 985-989 .
3.	张晓雨，孙浩翔，雷玉婷，王小雪，金长清，王影，王珩. 体检人群中血浆致动脉粥样硬化指数对代谢相关脂肪性肝病的预测价值. 中华健康管理学杂志. 2023(06): 437-443 .
4.	王雪飙，王育珊，姚华. 血清尿酸/肌酐比值与脑血流动力学及脑卒中相关危险因素分析. 新疆医科大学学报. 2023(08): 1105-1110 .
5.	陈超，陈冯梅. 血清尿酸/肌酐比值与老年人非酒精性脂肪肝的相关性研究. 医学信息. 2023(19): 71-74 .
6.	杨梦茹，韩睿. 非酒精性脂肪性肝病与慢性肾病关系的研究进展. 临床肝胆病杂志. 2022(11): 2586-2591 . 本站查看
7.	刘万年，张国富，刘迟利，姜静，王永斌，李文龙，杨中智，吴卫东. 河南省新乡县农村成年居民非酒精性脂肪肝的患病现况及影响因素分析. 新乡医学院学报. 2022(11): 1025-1030+1035 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (405) PDF downloads(49)

Value of different Baveno Ⅶ-based criteria in screening for high-risk esophageal and gastric varices in advanced chronic liver disease

DOI: 10.3969/j.issn.1001-5256.2023.04.012